Navigation Links
GIBCO MarrowMAX Bone Marrow Medium from Invitrogen

ProductsGIBCO MarrowMAX Bone Marrow Medium from Invitrogen
Company Invitrogen
Item GIBCO MarrowMAX Bone Marrow Medium
Price 
Description MarrowMAX Bone Marrow Medium
Info InvitrogenInvitrogen
Invitrogen Corporation
1600 Faraday Ave.
Carlsbad, CA 92008

Call Invitrogen to buy products (US and Canada only; other locations use numbers below)
USA Canada 1-866-521-4270
Customer Service: 800-955-6288
Tech Support: 800-955-6288 ext. 2
Fax Number: 760-603-7229
Web Site: http://www.invitrogen.com
NOTE: Price information is approximate list price and actual prices may vary.

Related biology products :

1. GIBCO Dulbeccos Modified Eagle Medium (D-MEM); powder (high glucose) from Invitrogen
2. GIBCO CD 293 AGT from Invitrogen
3. GIBCO Iscoves Modified Dulbeccos Medium (IMDM); powder from Invitrogen
4. GIBCO RPMI Medium 1640; powder from Invitrogen
5. GIBCO AmnioMAX-C100 Basal Medium liquid from Invitrogen
6. GIBCO RPMI Medium 1640; powder from Invitrogen
7. GIBCO Earles Balanced Salt Solution (EBSS) (1X); liquid from Invitrogen
8. GIBCO Bovine Serum from Invitrogen
9. GIBCO Graces Insect Cell Culture Medium; powder from Invitrogen
10. GIBCO Newborn Calf Serum from Invitrogen
11. GIBCO Sf-900 II SFM (1X) liquid from Invitrogen
... APAgene kits are designed to rapidly ... using our patented APA Technology. ... at an extraordinarily competitive price. All ... kit. The Locator Kit can be ...
... one of the several main MAP kinase ... a sensitive reporter for studying gene regulation ... in sensitivity in comparison to the standard ... the oxidative carboxylation of luciferin, a reaction ...
Recommended for supporting the growth of anchorage-dependent cells including human and mouse stromal cells, mesenchymal cells and cell lines....
... FailSafe™ PCR System is the only PCR ... time and every time. It provides accuracy, ... the source or the property of the ... PCR Enzyme Mix, a unique blend of ...
Biology Products:
(Date:7/31/2015)... , Jul. 31, 2015 NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market and ... has filed provisional patent 62/198989 for ELECTRONIC ... highlights a method to advance crypto-currencies such as Bitcoin ... a common, uniform way to manage all payments.  ...
(Date:7/23/2015)... 23, 2015 Aware, Inc. (NASDAQ: AWRE ), ... financial results for its second quarter ended June 30, 2015.  ... was $4.5 million, a decrease of 33% compared to $6.8 ... the second quarter of 2015 was $0.3 million, or $0.01 ... per diluted share, in the same period a year ago.  ...
(Date:7/20/2015)... , July 20, 2015  Acuity Market Intelligence,s ... The Convergence of Commerce and Privacy" forecasts that ... biometric apps will be downloaded to smart mobile ... mobile biometrics market is projected to generate more ... during the seven-year forecast period.    ...
Breaking Biology News(10 mins):NXT-ID Patents Electronic Crypto-Currency Management Technology 2NXT-ID Patents Electronic Crypto-Currency Management Technology 3NXT-ID Patents Electronic Crypto-Currency Management Technology 4Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6Biometrics on Smart Mobile Devices to Redefine Digital Identity with 12.9 Billion Biometric App Downloads between 2014 and 2020 2
... children were born in public clinics in Denmark, projecting a net ... 50 years respectively. The authors of the study calculated that reductions ... to cost savings of 67 - 111 million for the Danish ... 50 years of age, the government would have lost 74 - ...
... 6, 2011 A first-of-its-kind study of a patient with lung ... the Virginia G. Piper Cancer Center at Scottsdale Healthcare at the ... Researchers for the first time sequenced the entire DNA and RNA ... Glen Weiss, the first author of the study, which will be ...
... bird, the statuesque whooping crane ( Grus americana ), is ... Smithsonian,s National Zoological Park. An 11-year-old male whooping crane named ... now on exhibit in the nation,s capital. Whooping cranes are ... States. There are only eight other zoos in the U.S. ...
Cached Biology News:The long-term fiscal impact of funding cuts for IVF in Denmark 2First whole-genome lung cancer study by TGen and Virginia G. Piper Cancer Center set for conference 2National Zoo Welcomes Whooping Crane 2
(Date:7/31/2015)... , July 31, 2015 China Cord ... China,s leading provider of cord blood ... cell storage services, today announced that the Company has ... U.S. Securities and Exchange Commission. The filed Form 20-F ... March 31, 2015. The Form 20-F can be accessed ...
(Date:7/30/2015)... , July 30, 2015   GenoSpace , ... the interpretation and analysis of genomic and other ... has joined the company as Vice President ... http://photos.prnewswire.com/prnh/20150730/250931 "GenoSpace partners ... integrate, interpret, analyze and explore complex sets of ...
(Date:7/30/2015)... ... July 30, 2015 , ... Leading regenerative veterinary medicine company, ... canine osteoarthritis stem cell product, currently under development for FDA approval. The product ... marketed in the US by Aratana. This product, termed AT-016, is an allogeneic ...
(Date:7/30/2015)... Ascendis Pharma A/S (Nasdaq: ASND ... TransCon technology to address significant unmet medical needs, ... Phase 2 study to evaluate the safety and ... treatment-naïve, pre-pubertal children with growth hormone deficiency, or ... the top-line results from our Phase 2 pediatric ...
Breaking Biology Technology:China Cord Blood Corporation Files Its Annual Report on Form 20-F 2GenoSpace Introduces Matthew Fischer as Vice President of Sales and Marketing 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7